News

Tregs control atherosclerosis
Enlarge image

ResearchSwedenSwitzerlandGermany

Tregs control atherosclerosis

18.02.2013 - European researchers have shown that depletion of immunosuppressant T lymphocytes boosts hypercholersterolemia and atherosclerosis in mice.

The findings lay the foundation for cell-based therapies against the fatal disease. Until now, several studies had supported the assumption that FoxP3-positive CD4+CD25+ T cells block the inflammatory processes that lead to the formation of atherosclerotic plaques in the blood vessels, which can cause cardiac infarction and stroke. But the team under Göran Hansson from Swedish Karolinska Institute was the first to demonstrate the effect in genetically engineered DEREG mice. Those mice express the diphteria toxin (DT) under control of a Treg-specific FoxP3 promotor.

Lethally irradiated, atherosclerosis-prone, low-density lipoprotein receptor–deficient (Ldlr/) mice received DEREG bone marrow and were injected with DT to eliminate FOXP3+ Tregs. The depletion caused a 2.1-fold increase in atherosclerosis without a concomitant increase in vascular inflammation. The mice also exhibited a 1.7-fold increase in plasma cholesterol and an atherogenic lipoprotein profile with increased levels of VLDL. Clearance of VLDL and chylomicron remnants was hampered, leading to accumulation of cholesterol-rich particles in the circulation. Functional and protein analyses complemented by gene expression array identified reduced protein expression of sortilin-1 in liver and increased plasma enzyme activity of lipoprotein lipase, hepatic lipase, and phospholipid transfer protein as mediators of the altered lipid phenotype. The results prove that FOXP3+ Tregs block atherosclerosis by modulating lipoprotein metabolism.

The findings are good news for drug developers, as Milan-based researchers have recently demonstrated that it is feasible to isolate functional Tregs and expand them in vitro. The patent has already been licenced to German T-cell Europe, which will use the technology for inducing immune tolerance after organ transplantation.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/tregs-control-atherosclerosis.html

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

FinancingSwitzerlandGermanyNetherlandsFrance

26.09.2014 Biotechnology has made the news in the stock market this month, as a wave of companies announced plans to launch IPOs on European exchanges later this year.

ResearchGermany

25.09.2014 After being hit hard by the Andromeda trial data falsification scandal, German biotech Evotec is moving back into calmer waters with new MS research projects.

FinancingNetherlands

23.09.2014 Dutch Biotech VC firm Aglaia has launched a new US$65m fund targeted towards biotechnology startups working on groundbreaking technologies aimed at preventing and curing cancer.

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ADDEX3.51 CHF12.14%
  • STRATEC BIOMEDICAL41.09 EUR4.55%
  • MEDIGENE4.00 EUR2.30%

FLOP

  • CYTOS0.18 CHF-5.26%
  • MOLOGEN6.60 EUR-2.22%
  • SANTHERA86.95 CHF-1.92%

TOP

  • PAION3.22 EUR33.6%
  • CO.DON3.14 EUR27.6%
  • FORMYCON8.20 EUR16.3%

FLOP

  • CYTOS0.18 CHF-28.0%
  • EVOTEC3.10 EUR-16.7%
  • MOLOGEN6.60 EUR-12.8%

TOP

  • SANTHERA86.95 CHF2146.8%
  • PAION3.22 EUR238.9%
  • CO.DON3.14 EUR223.7%

FLOP

  • CYTOS0.18 CHF-95.3%
  • MOLOGEN6.60 EUR-44.5%
  • 4SC1.04 EUR-44.4%

No liability assumed, Date: 01.10.2014